Celgene Corp (CELG)

123.45
0.23 0.19
NASDAQ : Health Care
Prev Close 123.22
Open 123.72
Day Low/High 122.95 / 124.13
52 Wk Low/High 92.98 / 137.54
Volume 2.82M
Avg Volume 4.17M
Exchange NASDAQ
Shares Outstanding 777.97M
Market Cap 95.98B
EPS 2.60
P/E Ratio 49.55
Div & Yield N.A. (N.A)

Latest News

Dow, S&P 500 Retreat From Rally as Health Care Selloff Interrupts Fed Boost

Dow, S&P 500 Retreat From Rally as Health Care Selloff Interrupts Fed Boost

Investor sentiment soured on Thursday as a selloff in health care challenges optimism over the Federal Reserve's decision to raise interest rates.

S&P 500 Trades Lower as Health Care Sells Off, Crude Fluctuates

S&P 500 Trades Lower as Health Care Sells Off, Crude Fluctuates

Stocks are slightly lower by early afternoon Thursday as a selloff in health care challenges optimism over the Federal Reserve's decision to raise interest rates.

Stocks Extend Declines as Biogen Leads Health Care Selloff

Stocks Extend Declines as Biogen Leads Health Care Selloff

Early morning gains quickly evaporate on Thursday as a selloff in health care overshadows the Federal Reserve's decision a day earlier to raise interest rates.

Cramer: The Airlines and Health-Care Names Are Really Soaring

Cramer: The Airlines and Health-Care Names Are Really Soaring

This reversal has been incredible to watch.

It's Time to Add Credit Suisse's Top 10 Stocks for 2017 to Your Portfolio

It's Time to Add Credit Suisse's Top 10 Stocks for 2017 to Your Portfolio

Research firm Credit Suisse has put together a list of 140 "top ideas" covered by their analysts.

Credit Suisse's Top 10 Stocks for 2017

Credit Suisse's Top 10 Stocks for 2017

Companies like Apple, Facebook, J.P. Morgan and others are among Credit Suisse's top picks for 2017.

Allergan, Schlumberger, Caterpillar: Doug Kass' Views

Allergan, Schlumberger, Caterpillar: Doug Kass' Views

Doug Kass shares his thoughts on Allergan, and says that Caterpillar remains purr-fect for shorting.

Celgene's Deep Pipeline Can Reassure Investors

Celgene's Deep Pipeline Can Reassure Investors

This biotech company is trading at a bargain compared to its peer group.

These Trends Aren't Your Friends

There are signs of how narrow the market has become.

Oral OTEZLA® (Apremilast) Demonstrated Significant Improvement Versus Placebo In Trial Of Patients With Moderate Plaque Psoriasis Who Were Naïve To Systemic And Biologic Therapy

Oral OTEZLA® (Apremilast) Demonstrated Significant Improvement Versus Placebo In Trial Of Patients With Moderate Plaque Psoriasis Who Were Naïve To Systemic And Biologic Therapy

Celgene Corporation (NASDAQ:CELG) today announced that results from its phase 4 UNVEIL trial evaluating OTEZLA ® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), in patients with...

Celgene To Present New Data From Clinical Trials On Oral OTEZLA® (apremilast) At American Academy Of Dermatology Congress

Celgene To Present New Data From Clinical Trials On Oral OTEZLA® (apremilast) At American Academy Of Dermatology Congress

Celgene Corporation (NASDAQ:CELG) today announced that findings from ongoing clinical trials of OTEZLA ® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), conducted in patients with...

FDA Accepts New Drug Application And Grants Priority Review For Enasidenib In Relapsed Or Refractory AML With An IDH2 Mutation

FDA Accepts New Drug Application And Grants Priority Review For Enasidenib In Relapsed Or Refractory AML With An IDH2 Mutation

Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals (NASDAQ:AGIO) today announced that the U.

PaylPal, CH Robinson Worldwide, Texas Instruments: 'Mad Money' Lightning Round

PaylPal, CH Robinson Worldwide, Texas Instruments: 'Mad Money' Lightning Round

Jim Cramer is bullish on PaylPal, CH Robinson Worldwide, Texas Instruments and NXP Semiconductors.

Here's Why Buffett Is So Bullish About This Market: Cramer's 'Mad Money' Recap (Monday 2/27/17)

Here's Why Buffett Is So Bullish About This Market: Cramer's 'Mad Money' Recap (Monday 2/27/17)

Jim Cramer highlight's Buffett's confidence in American businesses and stocks, and his critique of high fees charged by money managers.

Market Waiting for Trump's Speech

Buffett's Apple buy fails to ignite investor interest.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Celgene Corporation To Webcast At Upcoming Investor Conferences

Celgene Corporation To Webcast At Upcoming Investor Conferences

Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences where Celgene management will provide an overview of the Company.

IBM, Apple, Amazon: Doug Kass' Views

IBM, Apple, Amazon: Doug Kass' Views

Doug Kass shares his thoughts on peak housing, and also discusses Fannie Mae and Freddie Mac's recent kneecapping.

Celgene Announces Retirement Of President And Chief Operating Officer, Jacqualyn Fouse, Ph.D. And Promotion Of Scott Smith To President And Chief Operating Officer

Celgene Announces Retirement Of President And Chief Operating Officer, Jacqualyn Fouse, Ph.D. And Promotion Of Scott Smith To President And Chief Operating Officer

Celgene Corporation (NASDAQ:CELG) today announced that President and Chief Operating Officer (COO) Jacqualyn ("Jackie") Fouse, Ph.

Go With Allergan, Celgene and 'Big Mo'

Go With Allergan, Celgene and 'Big Mo'

These two large-cap drug giants should be core parts of any well-diversified portfolio.

Market Not Laced With Kool-Aid; Apple Could Become a Consumer-Products Company: Jim Cramer's View

Market Not Laced With Kool-Aid; Apple Could Become a Consumer-Products Company: Jim Cramer's View

Cramer shares his views on how tired he is of hearing about Kool-Aid, and wonders if Apple could be valued as a consumer-products company one day.

Procter & Gamble, Apple, Home Depot: Doug Kass' Views

Procter & Gamble, Apple, Home Depot: Doug Kass' Views

Doug Kass shares his thoughts on Procter & Gamble, and wonders if the market is about to slip its moorings.

Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial

Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial

Ozanimod is part of Celgene's strategy to grow its inflammation and immunology business as a diversification hedge away from Revlimid, the blockbuster blood cancer drug.

Celgene Announces Positive Results From Phase III SUNBEAM Trial Of Oral Ozanimod In Patients With Relapsing Multiple Sclerosis

Celgene Announces Positive Results From Phase III SUNBEAM Trial Of Oral Ozanimod In Patients With Relapsing Multiple Sclerosis

Celgene Corporation (NASDAQ: CELG) today announced that its phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with...

Cramer: If You Think I'm Drinking the Kool-Aid, Swallow This

Cramer: If You Think I'm Drinking the Kool-Aid, Swallow This

Some tried-and-true indicators show what's really going on with the market.

Celgene Could Have One More Powerful Move Higher

Celgene Could Have One More Powerful Move Higher

Celgene's rebound off the January lows could soon develop into a fresh move higher.

Chesapeake Energy, Priceline, Schlumberger, ZELTIQ : 'Mad Money' Lightning Round

Chesapeake Energy, Priceline, Schlumberger, ZELTIQ : 'Mad Money' Lightning Round

Jim Cramer's bullish on ZELTIQ Aesthetics, Chesapeake Energy, Priceline Group and more.